D’Arcy v Myriad: Australia’s High Court deals blow to natural product patents
07-10-2015
360b / Shutterstock.com
Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Myriad, cancer, patent, genes
